Jan 02nd 2013 - Edison Investment Research today published a report on Epigenomics entitled "PMA Filing On Back Of Non-inferiority". In summary, the report says:
Epigenomics expects to complete its PMA submission for Epi proColon, following the completion of its head-to-head study with faecal immunochemical testing (FIT) in the detection of colorectal cancer (CRC). The study, which forms an integral part of the final module of the PMA submission, met its key end point of non-inferiority with respect to sensitivity. Thus, the key question for investors now is whether Epi proColon can find a place in the rapidly evolving commercial landscape for CRC screening and how successfully Epigenomics can compete with larger players.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »